LAKEWOOD, Colo., Oct. 25 /PRNewswire/ -- Andrew Tofe, PhD, President and CEO of CeraPedics, will make a presentation at Medtech Insight’s “In Spine & Orthopedics” conference on November 2 at 9:30 a.m. at the Westin Stonebriar Resort in North Dallas, Texas. Dr. Tofe will discuss the development of P-15 Putty, which is an orthopedic bone graft material consisting of the synthetic P-15 peptide bound to anorganic bone mineral (ABM) suspended in an inert hydrogel carrier.
According to Dr. Tofe, “P-15 differs from existing commercially available growth factors in that it does not convert undifferentiated cells into bone cells. Instead, it initiates a chain of cellular changes that kick starts the production of new bone. These characteristics make P-15 not only very effective in promoting new bone growth but also very safe.”
CeraPedics is a privately held company focused on the development of synthetic bone graft products incorporating its proprietary P-15 technology. In September, CeraPedics filed for an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to conduct a clinical investigation to study the safety and efficacy of P-15 Putty when used for spine fusion. P-15 was previously approved by the FDA in 1999 for use in dental bone growth applications.
According to Medtech Insight’s web site, the “In Spine & Orthopedics” conference “will provide a focused, single-track forum for our large group of emerging, privately held spine and orthopedic companies to present to an audience of venture capitalists, investment bankers, corporate business development executives, and clinicians for purposes of funding, acquisition, and/or strategic partnership.”
CeraPedics, L.L.C.
CONTACT: Don Freeman, Business Development Manager of CeraPedics, L.L.C.,+1-303-980-1781, dfreeman@cerapedics.com; or Matt Swetonic of TheDilenschneider Group, +1-212-922-0900, mswetonic@dgi-nyc.com, forCeraPedics, L.L.C.
